Immune activation alters cellular and humoral responses to yellow fever 17D vaccine

被引:158
|
作者
Muyanja, Enoch [1 ]
Ssemaganda, Aloysius [1 ]
Ngauv, Pearline [2 ]
Cubas, Rafael [2 ]
Perrin, Helene [2 ]
Srinivasan, Divya [2 ]
Canderan, Glenda [2 ]
Lawson, Benton [3 ]
Kopycinski, Jakub [4 ]
Graham, Amanda S. [5 ]
Rowe, Dawne K. [5 ]
Smith, Michaela J. [5 ]
Isern, Sharon [5 ]
Michael, Scott [5 ]
Silvestri, Guido [3 ]
Vanderford, Thomas H. [3 ]
Castro, Erika [6 ]
Pantaleo, Giuseppe [6 ,7 ]
Singer, Joel [8 ]
Gillmour, Jill [4 ]
Kiwanuka, Noah [1 ,9 ]
Nanvubya, Annet [1 ]
Schmidt, Claudia [9 ]
Birungi, Josephine [1 ]
Cox, Josephine [4 ]
Haddad, Elias K. [2 ]
Kaleebu, Pontiano [1 ,10 ]
Fast, Patricia [11 ]
Sekaly, Rafick-Pierre [2 ]
Trautmann, Lydie [2 ]
机构
[1] Uganda Virus Res Inst, Uganda Virus Res Inst Int AIDS Vaccine Initiat UV, Entebbe, Uganda
[2] Vaccine & Gene Therapy Inst Florida, Port St Lucie, FL USA
[3] Emory Vaccine Ctr, Ctr AIDS Res, Virol Core, Atlanta, GA USA
[4] Internat AIDS Vaccine Initiat, Human Immunol Lab, London, England
[5] Florida Gulf Coast Univ, Dept Biol Sci, Ft Myers, FL USA
[6] Div Immunol & Allergy, Lausanne, Switzerland
[7] Univ Lausanne, Univ Lausanne Hosp, Swiss Vaccine Res Inst, Lausanne, Switzerland
[8] Canadian Inst Hlth Res, Canadian HIV Trials Network, Vancouver, BC, Canada
[9] Makerere Univ, Sch Publ Hlth, Entebbe, Uganda
[10] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda
[11] Int AIDS Vaccine Initiat, New York, NY USA
来源
JOURNAL OF CLINICAL INVESTIGATION | 2014年 / 124卷 / 07期
基金
比尔及梅琳达.盖茨基金会;
关键词
MEMORY B-CELLS; BLOOD MONOCYTES; BCG VACCINATION; HIV-INFECTION; DOUBLE-BLIND; VIRUS; IMMUNOGENICITY; SAFETY; UK; IMMUNIZATION;
D O I
10.1172/JCI75429
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background. Defining the parameters that modulate vaccine responses in African populations will be imperative to design effective vaccines for protection against HIV, malaria, tuberculosis, and dengue virus infections. This study aimed to evaluate the contribution of the patient-specific immune microenvironrnent to the response to the licensed yellow fever vaccine 17D (YF-17D) in an African cohort. Methods. We compared responses to YF-17D in 50 volunteers in Entebbe, Uganda, and 50 volunteers in Lausanne, Switzerland. We measured the CD8(+) T cell and B cell responses induced by YF-17D and correlated them with immune parameters analyzed by flow cytometry prior to vaccination. Results. We showed that YF-17D-induced CD8(+) T cell and B cell responses were substantially lower in immunized individuals from Entebbe compared with immunized individuals from Lausanne. The impaired vaccine response in the Entebbe cohort associated with reduced YF-17D replication. Prior to vaccination, we observed higher frequencies of exhausted and activated NK cells, differentiated T and B cell subsets and proinflammatory monocytes, suggesting an activated immune microenvironment in the Entebbe volunteers. Interestingly, activation of CD8(+) T cells and B cells as well as proinflammatory monocytes at baseline negatively correlated with YF-17D-neutralizing antibody titers after vaccination. Additionally, memory T and B cell responses in preimmunized volunteers exhibited reduced persistence in the Entebbe cohort but were boosted by a second vaccination. Conclusion. Together, these results demonstrate that an activated immune microenvironment prior to vaccination impedes efficacy of the YF-17D vaccine in an African cohort and suggest that vaccine regimens may need to be boosted in African populations to achieve efficient immunity.
引用
收藏
页码:3147 / 3158
页数:12
相关论文
共 50 条
  • [41] Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day
    Natalie D. Collins
    Alan D. T. Barrett
    Current Infectious Disease Reports, 2017, 19
  • [42] A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
    Oreshkova, Nadia
    Myeni, Sebenzile K.
    Mishra, Niraj
    Albulescu, Irina C.
    Dalebout, Tim J.
    Snijder, Eric J.
    Bredenbeek, Peter J.
    Dallmeier, Kai
    Kikkert, Marjolein
    VACCINES, 2021, 9 (12)
  • [43] COMPARATIVE CLINICAL-STUDY OF A NEW 17D THERMOSTABLE YELLOW-FEVER VACCINE
    ROCHE, JC
    JOUAN, A
    BRISOU, B
    RODHAIN, R
    FRITZELL, B
    HANNOUN, C
    VACCINE, 1986, 4 (03) : 163 - 165
  • [44] Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity
    Monath, Thomas P.
    Lee, Cynthia K.
    Julander, Justin G.
    Brown, Alicja
    Beasley, David W.
    Watts, Douglas M.
    Hayman, Edward
    Guertin, Patrick
    Makowiecki, Joseph
    Crowell, Joseph
    Levesque, Philip
    Bowick, Gavin C.
    Morin, Merribeth
    Fowler, Elizabeth
    Trent, Dennis W.
    VACCINE, 2010, 28 (22) : 3827 - 3840
  • [45] YELLOW FEVER VACCINE .5. ANTIBODY RESPONSE IN MONKEYS INOCULATED WITH GRADED DOSES OF 17D VACCINE
    MASON, RA
    TAURASO, NM
    GINN, RK
    OBRIEN, TC
    TRIMMER, RW
    APPLIED MICROBIOLOGY, 1972, 23 (05) : 908 - &
  • [46] CONSTRUCTION OF A RECOMBINANT YELLOW FEVER 17D CLONING VECTOR
    Kaltenborn, Z. P.
    Vogt, J.
    Spies, G.
    McElrath, M. J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (01) : 172 - 173
  • [48] Immunogenicity and Protective Efficacy of Aerosolized Live-Attenuated Yellow Fever 17D Vaccine in Mice
    Zhu, Feng
    Sun, Meng-Xu
    Zhao, Suo-Qun
    Qin, Cheng-Feng
    Wang, Jin-Hua
    Deng, Yong-Qiang
    VACCINES, 2024, 12 (08)
  • [49] ENCEPHALITIS IN A 13-YEAR-OLD BOY FOLLOWING 17D YELLOW-FEVER VACCINE
    SCHOUB, BD
    DOMMANN, CJ
    JOHNSON, S
    DOWNIE, C
    PATEL, PL
    JOURNAL OF INFECTION, 1990, 21 (01) : 105 - 106
  • [50] HUMAN-ANTIBODY RESPONSE TO IMMUNIZATION WITH 17D YELLOW-FEVER AND INACTIVATED TBE VACCINE
    KAYSER, M
    KLEIN, H
    PAASCH, I
    PILASKI, J
    BLENK, H
    HEEG, K
    JOURNAL OF MEDICAL VIROLOGY, 1985, 17 (01) : 35 - 45